#1 Breakout Stock (Inside) Telemental Health App to Disrupt $330 Billion Mental Health Crisis!

Breakout Alert: Saturday October 8, 2022 Mental Health, Meet Venture Capital Venture Capitalists And Buyout Firms Are Pouring Billions of Dollars Into Mental-Health Apps And Startups Hi 10XProTrader Member, This is Kevin Vander with “10XProTrader” delivering you your next premium stock for Monday 10/10 trading session is (Ticker: CEOS). Mental Health, Meet Venture Capital Venture capitalists and buyout firms are pouring billions of dollars into mental-health apps and startups. The digital mental health sector will reach $26 Billion by 2027 and has already seen a 15x rate of growth over the past 4 years, according to a new report by Telosity by Vinaj Ventures. Leading me to my latest discovery that I stumbled upon... This particular stock just released news regarding it's “Telemental Health App” aimed to aid in North America’s $330 Billion Mental Health Crisis which you'll learn more of below. Immediately turn your attention to Psykey Inc. (CEOS) PsyKey, Inc. is vertically integrated in the research & development, production, and commercialization of therapeutic and medicinal entheogenic, adaptogenic, nootropic ingredients and formulations for its premium functional product lines. Developed by its mycology and botany experts, PsyKey Inc.'s Cultivation and Crop Management Protocols have been created to build, manage, and secure a supply chain of quality medicinal ingredients. PsyKey is also engaged in the scientific development of patentable technologies pertaining to the composition, bioavailability, and targeted delivery of entheogen-based therapeutics. PsyKey, Inc. is engaged in the acquisition and development of healthcare companies for healthcare supplies and healthcare equipment. The company is engaged in the development of new healthcare technologies and will continue to develop additional markets through healthcare IT and other related entities. The Company has several bullish catalysts on the horizon and is poised to Disrupt the $330 Billion Mental Health sector with their latest Blockbuster News of its "Telemental Health App!" PsyKey Inc. (CEOS) Announces Beta Testing of its Telemental Health App Aimed to Aid in North America’s $330 Billion Mental Health Crisis CEOS announced it has completed the beta version of its Telehealth App PSYKEY LIVE. Accessibility to quality mental health support through qualified care providers can be an overwhelming task. According to Whitehouse.gov, an estimated $280 Billion was spent on mental health services in the United States in 2020. In Canada, over the past 20 years, mental health costs have increased by 646%, bringing the economic burden to an estimated $51 Billion per year, according to the Centre for Addiction and Mental Health (CAMH). This cost includes health care, lost productivity, and reductions in health-related quality of life. The PSYKEY LIVE App was created to streamline accessing mental health support services. The app is designed with ease of use and convenience at the forefront of importance, providing individuals direct access to mental health support providers via video conferencing, live chatting and more. The comprehensive App platform allows users to view profiles of care providers, schedule, and track appointments, and create individual private health profiles. These profiles can house users' private health records, medication use information, and any critical notes individuals may wish to disclose to the providers they choose. The PSYKEY LIVE App is now ready for real-world beta testing and will be utilized in various settings to fine-tune and optimize its functionality. Digital interaction and Telehealth have become more prevalent in recent years, especially under the health restrictions the world is currently dealing with. Not only does digital Telehealth offer convenience to all, but it also affords PSYKEY LIVE the ability to offer support to rural, remote, and high-risk communities across the country, bridging the gap and providing real accessibility. The Digital Mental Health Market – A Billion Do∙llar Oppor∙tunity Marc Schröder, managing partner at early-stage venture capital firm Maschmeyer Group Ventures, said mental health investment is kicking off now because the market is big and full of competition, which shows the need is there. Schröder was one of the first investors in mental well-being platform Modern Health, which is now valued at $1.17 Billion after closing a $74 Million Series D raise led by Founders Fund. Modern Health reached "unicorn" status in February, reports continued hypergrowth in the second quarter of 2021. The company has grown its team 104% in 2021 to support the rapidly growing demand for mental health support across the globe. “Last year was just the start,” he said. “Investors are jumping on board because the market is large and booming, and it can handle the competition. If you missed out on Modern Health, you can jump on the next one. This is the trend right now and is only going to grow.” So if you missed plays like Modern Health … This could be your final chance at mind boggling gains. Leading me to my latest discovery Psykey Inc. (CEOS) CEOS is my next stock that looks ready to move in a major way, so make sure you have it pulled up on your trading screen Monday morning. Last year, CEOS announced that the Company is transitioning into the Psychedelics Market. PsyKey Inc. Announces Discussions with Biotech Company & Psilocybin Fermentation Specialist, Zealous Inc. CEOS announced it has entered into discussions to establish a strategic partnership with biotechnology company, Zealous Inc. "Identifying and forming new partnerships is essential to building a solid foundation to expedite the development and launch of PsyKey's unique functional beverage and supplement product offerings," stated Amar Bhatal, President, Co-Founder PsyKey. Zealous Inc. is a Canadian Biotechnology company whose focus is the development of psilocybin and psilocin, commercially produced using its proprietary bioreactor fermentation technology. Zealous Inc's impressive bioengineering team includes ten PhDs who have a successful track record of producing 99+% pure cytosine, orotate, and beta-nicotinamide mononucleotide on a commercial scale. Zealous Inc. also has a successful history in product development and commercialization utilizing active compound identification, formula development, recipe design and optimization, as well as consumer trials and clinical studies. The Zealous team has over 15 years of experience in the food, beverage, and supplement industries. Senior management has successfully managed over 40 stock keeping units (SKU) and has launched 13 new products/formulas in both the United States and Canada. We are very excited about this oppor∙tunity. The Non-Disclosure Agreements (NDA's) are signed, and we have been in ongoing discussions with the Zealous Inc. team for several weeks to reach a mutually beneficial agreement. The biotechnology capabilities of Zealous Inc. demonstrate a proven track record in establishing product functionality. Their existing relationships with contract research firms and hospitals will allow us to potentially conduct future clinical trials of future PsyKey products; concluded Amar Bhatal. PsyKey will continue to develop additional strategic partnerships as it positions itself in the fast-evolving mushroom markets. With the psychedelic drug market projected to reach the multi-billion-do∙llar mark by 2027, working with a world-class mycologist and partnering with innovative companies like Zealous, whose goal is commercial production, PsyKey is building on its objectives of long-term growth and increased investor value. Global Psychedelics Market Is Expected To Reach $8 Billion By 2028 Over the last year, while most of us were distracted by the pandemic, the psychedelic industry exploded. Companies that had for years quietly pursued research and recruited investors went public. Dozens of startups launched. And venture capitalists began to pay serious attention. An industry that a year ago had a market cap of less than $1 Billion suddenly housed four companies that each individually had a billion-do∙llar valuation. The potential of the psychedelics industry has never been bigger. Some psychedelic drugs are extracted from plants or mushrooms, and some are synthetic (human-made). These drugs are now considered effective for patients with treatment-resistant depression, as they are fast-acting and long-lasting. Psychedelic Drugs Market Growing as Prevalence of Mental Health Issues are Increasing Globally The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept pace, precipitating a crisis in psychiatric medicine. A novel innovation is psychedelic drug-assisted psychotherapy - the medically approved use of MDMA, psilocybin, and LSD as a component of elevated psychotherapy programs. A report from ResearchAndMarkets said that mental disorders are an urgent health crisis worldwide, especially exacerbated by COVID-19. As per a study by Harvard, the medical cost of mental health conditions is estimated to rise to $6 Trillion by 2030. ResearchAndMarkets continued: "The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept pace, precipitating a crisis in psychiatric medicine. A novel innovation is psychedelic drug-assisted psychotherapy - the medically approved use of MDMA, psilocybin, and LSD as a component of elevated psychotherapy programs. North America is predicted to remain the largest region in the psychedelic drugs market due to a surge of clinical trials, massive investments, regulatory support, and widespread public awareness. Wall Street & Silicon Valley Leaders Are Rushing to Support Psychedelic Medicine As psilocybin boldly merges into modern pharmacopeia, the emerging field of psychedelic medicine continues forward amidst this electrifying renaissance. Pioneers such as MAPS, Usona Institute and Compass Pathways have been awarded the coveted “breakthrough status” for their psilocybin-based therapies by the US Food & Drug Administration. This designation marked a historic moment for the overall psychedelic revolution and has caught the attention of various notable investors from Wall Street and Silicon Valley. Peter Thiel, the notable venture capitalist backer of Compass Pathways, is the co-founder of PayPal and one of Facebook’s first major investors. He is also the chairman of Palantir Technologies, which as of today has a market cap of over $54BIL. Thiel’s combined investments in Palantir and Compass Pathways highlight the significant shift in attention towards psychedelics from big players in Wall Street and Silicon Valley. Looking at Thiel’s track record along with the significant attention towards psychedelics from big players in Wall Street and Silicon Valley, Thiel may be onto something by investing in the psilocybin sector! The UFC is looking to get involved with research into psychedelic drugs as a therapy for fighters' brain health. The UFC turned to Johns Hopkins study on psychedelic drugs as potential therapy for fighters. They have been in contact with Johns Hopkins University about its psychedelic studies with an eye toward seeing if the drugs can be helpful for fighters dealing with brain issues. UFC senior vice president of health and performance Jeff Novitzky told ESPN that the interest came from a segment from HBO's "Real Sports." Novitzky said White gave him a "directive" to look more into psychedelic research and he has been in contact with Johns Hopkins. The UFC has been a key funder of a professional athlete brain study being conducted by the Cleveland Clinic Lou Ruvo Center for Brain Health, contributing another $1 Million. Novitzky said the promotion could look to be a benefactor toward a psychedelic study with the added possibility of recruiting current or former UFC fighters to be part of the research. "Dana said, 'Hey, find out what this is about,'" Novitzky said. "To see if it does help with some traumatic brain injury, addiction, mental health problems. We want to be on board and we want to be first." Johns Hopkins is the nation's leader in research on the therapeutic effects of psychedelics such as psilocybin (mushrooms) and LSD. The Johns Hopkins Center for Psychedelic & Consciousness Research gained regulatory approval from the U.S. government in 2000 and has produced more than 60 pieces of peer-reviewed research. Currently, psilocybin and other psychedelics are classified by the U.S. government as ille∙gal Schedule I drugs, defined as drugs with a high potential for abuse or drugs that have no medical uses. However, views on psychedelics are changing. Lega∙lization of psychedelics for use in medicine is gaining momentum across the United States. Advances in lega∙lization, reports indicate that drug developers may soon submit some hallucinogens to the U.S. Food and Drug Administration (FDA) for approval to treat mental health disorders. In July 2022, the Biden Administration indicated that it expects FDA to approve MDMA and psilocybin as treatments for PTSD and depression, and that regulators will approve MDMA and psilocybin for designated "breakthrough therapies" for PTSD and depression. In 2018, the U.S. Food and Drug Administration named psilocybin a “breakthrough therapy” in treatment for severe depression, a designation the agency applies to drugs that in early trials demonstrate substantial improvement over existing treatments. The Bottom Line... The FDA is helping to create a MAJOR CATALYST that will put the psychedelics industry on the watch lists of major investors around the world and you’ll want to be in before them. The FDA has encouraged this research by granting “Breakthrough Therapy” status, a designation that accelerates the path to drug approval, to the study of multiple psychedelic drugs, and as I stated above in July 2022, the Biden Administration indicated that it expects FDA to approve MDMA and psilocybin as treatments for PTSD and depression, and that regulators will approve MDMA and psilocybin for designated "breakthrough therapies" for PTSD and depression. In 2019, the FDA approved 1 of these drugs, esketamine as a therapy for treatment-resistant depression. More recently, researchers published promising results from an FDA-approved phase 2 trial of psilocybin as a treatment for major depressive disorder. Perhaps most striking, in June researchers published remarkable results from a phase 3 trial—the final phase before seeking FDA approval—studying 3,4-methyl-enedioxymethamphetamine (MDMA) as a treatment for posttraumatic stress disorder. Two-thirds of study participants who received MDMA-assisted therapy no longer qualified for a PTSD diagnosis 2 months after treatment, compared with 32% who received therapy alone. No serious adverse side effects were reported. If the results of a second phase 3 trial are similarly positive, the FDA could approve the treatment as early as 2022. This could prove to be a HUGE CATALYST for the company, If we could see an FDA Approval, who knows what could happen to the share price of CEOS... FDA Approval could send the share price of CEOS soaring! I am urging all of our members to add CEOS to the top of your watch list right now, and have it pulled up on your trading screen Monday morning at the opening bell! Yours for greater gains, Kevin Vander 10XProTrader.com Investment Research P.S. Please do NOT forward this new alert to anyone. This alert is private for the 10XProTrader community! © 2022 10XProTrader.com, All Rights Reserved. 10XProTrader is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. This communication is a paid advertisement. 10XProTrader.coms is owned and operated by 10X Media LLC, which is a Florida based Limited Liability Company and/or its subsidiaries and/or affiliates ("Company," "we," or "us") have been compensated $25,000 USD to disseminate this communication. Please review the full disc∙laimer at [( for important information about this advertisement. © 2022 10XProTrader. All rights reserved., 340 Royal Poinciana Way Suite 317, 33480, Palm Beach, United States You may [unsubscribe]( or [change your contact details]( at any time.